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Abstract
Objective To assess the frequency and nature of adverse events to
patients in selected hospitals in developing or transitional economies.
Design Retrospective medical record review of hospital admissions
during 2005 in eight countries.
SettingMinistries of Health of Egypt, Jordan, Kenya, Morocco, Tunisia,
Sudan, South Africa and Yemen; the World Health Organisation (WHO)
Eastern Mediterranean and African Regions (EMRO and AFRO), and
WHO Patient Safety.
Participants Convenience sample of 26 hospitals from which 15 548
patient records were randomly sampled.
Main outcomemeasures Two stage screening. Initial screening based
on 18 explicit criteria. Records that screened positive were then reviewed
by a senior physician for determination of adverse event, its
preventability, and the resulting disability.
Results Of the 15 548 records reviewed, 8.2% showed at least one
adverse event, with a range of 2.5% to 18.4% per country. Of these
events, 83% were judged to be preventable, while about 30% were
associated with death of the patient. About 34% adverse events were
from therapeutic errors in relatively non-complex clinical situations.
Inadequate training and supervision of clinical staff or the failure to follow
policies or protocols contributed to most events.
ConclusionsUnsafe patient care represents a serious and considerable
danger to patients in the hospitals that were studied, and hence should
be a high priority public health problem. Many other developing and
transitional economies will probably share similar rates of harm and
similar contributory factors. The convenience sampling of hospitals might
limit the interpretation of results, but the identified adverse event rates
show an estimate that should stimulate and facilitate the urgent institution
of appropriate remedial action and also to trigger more research.
Prevention of these adverse events will be complex and involves
improving basic clinical processes and does not simply depend on the
provision of more resources.
Introduction
Preventable harm to patients resulting from their healthcare is
unacceptable at any time. Patient safety is first and foremost a
clinical problem, but it is also an important cause of wasted
resources. Keeping patients safe can also be viewed as a public
health problem and a human rights issue.1 Documentation of
the scale of iatrogenic harm to patients has been accelerating
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since 1991, with one of the first hospital population studies by
Brennan et al in NewYork state.2 Studies progressed to national
estimates,3-5 and the focus moved from negligence to
preventability. Results suggested that rates of adverse events in
patients in hospital in the developed world were much higher
than previously thought, with multiple studies showing rates of
at least 8%.6 Of these adverse events, more than 50% were
judged to be preventable, and a worrying number of the patients
experienced permanent disability or death as a result of the
events. These reports suggest that the deaths of between 0.5%
and 2% of patients in hospital are associated with an adverse
event, which was often, but not always, preventable. These
studies would rank harm from healthcare high on the list of all
causes of death for the countries being studied. All published
studies to date, however, have been from developed countries,
with no reports from developing or transitional economies. This
knowledge gap is a serious limitation to understanding the extent
of the problem at the global level and, more importantly, in
specific countries. The importance of this gap must not be
underestimated. Health systems in developing and transitional
countries face severe health threats and challenges in a context
of scarce resources and weak infrastructure. Understanding
whether, howmuch, why, and how patients are harmed through
their respective healthcare systems is essential to inform the
global health policy agenda in these countries and to adopt the
most effective and efficient corrective actions.
The first global approach to dealing with patient safety came
with the passing of resolutionWHAA55.18 by theWorld Health
Assembly in 2002 urging the World Health Organization and
its member states to pay the closest possible attention to the
problem of patient safety, with five specific topics for action.
One of these was the encouragement of research into the size
and nature of the problem of harm to patients. TheWHOWorld
Alliance for Patient Safety7 (WHOPatient Safety) in conjunction
with theMinistries of Health of Egypt, Jordan, Kenya,Morocco,
Tunisia, South Africa, Sudan, and Yemen and theWHOEastern
Mediterranean and African Regions (EMRO and AFRO) took
up the challenge of estimating the extent of harm that was caused
by healthcare in a selection of hospitals in these countries. The
research project started in 2006with two objectives. The primary
goal was to assess the frequency, cause, and preventability of
adverse events in patients in hospital in the participating
countries, all of which are either low income countries or
countries in economic transition. Secondly, the study aimed to
examine the feasibility of using the established methods of
review of records in resource poor healthcare systems in which
medical records might be less comprehensive. Notwithstanding
the documented limitations of record review, it was chosen
because it was the most commonly published method of
measurement of rates of harm at a population level and also
there was little alternative.
Methods
Design
This was a retrospective review of randomly selected medical
records of patients in hospital in a convenience sample of 26
hospitals from eight developing and transitional countries.
Setting and population
The study was performed in hospitals from Egypt, Jordan,
Kenya, Morocco, South Africa, Sudan, Tunisia, and Yemen.
These countries have a cumulative population of nearly 265
million, about a third of whom live below the poverty line.8
There is an average health expenditure of $133 (£84, €101) per
head. The population sample was medical, surgical, paediatric,
and obstetric inpatients in acute care public or private hospitals.
Selection of hospital and sampling of records
The individual national teams invited hospitals to participate in
the study. Because of the logistical and other challenges of
conducting multicentre research in developing countries, we
resolved a priori to use a convenience, though
non-representative, sample of hospitals. This resulted in
over-representation of large teaching and urban hospitals in
each national sample. In total 26 hospitals were selected from
the eight countries (two to six hospitals per country): 13 teaching
hospitals, 23 general public hospitals (includes the 13 teaching
hospitals), one obstetric hospital (>15 000 admissions), one
paediatric hospital (10 000 admissions), and one private hospital.
The selected hospitals had 13 722 beds and admitted about 560
000 patients in 2005.
At each selected hospital, a list of all admissions for 2005 was
generated. From this list a random sample of over 600 patient
records was obtained, as we estimated that up to 500 completed
records were required. At least 450 records per site were useable
for the study and sometimes many in excess of that figure. The
excess was allowed to cater for records that could not be tracked
or were too incomplete to be evaluated. Same day admissions
were not eligible for inclusion.
Definitions
An adverse event was defined as an unintended injury that
resulted in temporary or permanent disability or death (including
increased length of stay or readmission) and that was associated
with healthcare management rather than the underlying disease
process. If more than one adverse event was identified within
the index admission, only the most serious one was described
and counted. Thus the total number of admissions associated
with an adverse event is being estimated. An index admission
is associated with an adverse event, regardless of whether it
occurred before and contributing to or during the index
admission.2 3
Preventability implied that the adverse event could have been
averted with different management or treatment. Generally, for
an adverse event to be judged as preventable, the reviewer
needed to establish that there was a process failure because of
non-compliance with accepted practices. This failure could
include system and clinical processes. The appropriate standard
for the reviewer to apply in this context was the current expected
level of performance for the average practitioner who treats this
type of problem in the country in question. Reviewers used a
judgment scale (see below).
Organisation of data collection
Country research teams were multidisciplinary and comprised
epidemiologists, medical record specialists, healthcare
professionals, and, in most cases, representatives from the
Ministry of Health, who provided the necessary links with the
health policy environment. Teamswere responsible for selection
and training of local reviewers, data collection, and web based
data entry. They received technical support from the principal
investigators and logistic support from theWHO regional office.
Review staff were selected in each country on the basis of
relevant clinical experience, interest and availability to
participate, fluency in English, and familiarity with the local
language. Review teams were largely made up of experienced
nurses and senior doctors with internal medicine, surgical, or
anaesthetic backgrounds; all underwent training. Training was
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performed at “learning sessions” of all teams combined, then
continued with international and local research team leaders in
the respective countries.
The central project office supported web based data entry. Data
were exported from data entry in Excel files and then cleaned
and analysed centrally in SAS. In addition to this paper,
technical reports have been provided to WHO and the
participating countries.
Process of review of medical records
Traditional two stage methods were used. The primary review
was an initial screening stage in which nurses, or, in some
countries, junior doctors, were trained to review the selected
medical records for the presence of one or more of 18 explicit
criteria (form RF1). A senior physician then reviewed records
that screened positive for one or more of the 18 criteria to
determine the presence of an adverse event and its preventability
(secondary review, formRF2) (see appendix 1 and 2 on bmj.com
for the RF1 and RF2 forms). Because of available resources
and on the basis of previous publications,6 a single physician
reviewed the records, rather than duplicate review, which has
been used in some large studies.2 3 A more recent publication
supports this approach.9 The record review tools used in this
study were adapted from those used in the Australian study.3
For use in the French speaking countries one of the authors
translated the review tools and instruction guide into French.
An injury or complication was judged to be an adverse event if
it was associated with death, disability at discharge, or prolonged
stay in hospital and received a causation rating of at least 2 on
a 1-6 point causation scale (see box 1). This is the same
threshold that has been previously used3 but is different from
the causation threshold in the initial publication that used these
methods,2which used at least 4, rather than 2. The adverse event
was preventable if rated higher than 3, on a 1-6 point
preventability scale.
Reliability study
Assessment of reliability was built into the initial design of the
study with the intention of independent double blind review of
a random 10% sample of all records at both the primary and
secondary review stages.
Results
The conduct of this study was challenging logistically for many
reasons, including distance and communication. These
challenges account in large part for the duration of the study,
the need for a convenience sample of hospitals within each
country, and the absence of reliability testing of the secondary
review. Identification of hospitals, records for review, and
recruitment of reviewers started in 2006 and training of teams
continued until 2008. Data collection occurred mostly during
2007 and analysis was completed in 2008, with reports being
provided to WHO and discussed with participating countries.
Of the 18 146 records that were initially selected for review, in
605 (3.3%) there were insufficient data to positively identify
the patient, and 1443 (7.9%) records could not be located. It is
unclear where there was a systematic reason for the
unavailability of these records, but we believe that it is more
likely to be a random effect reflecting the management of
medical records and, given the large sample size, should not
significantly affect the findings on adverse event rate. There
was no way to further elucidate this issue. Therefore nearly 89%
of all selected records were available for review, of which 3%
were duplicates. The review data from the 15 548 remaining
records forms the basis for the subsequent results.
Table 1⇓ gives the number of primary and secondary reviews
and the proportion of positive findings. A total of 15 548
admissions underwent primary review, and the number in each
country varied from nearly 1000 in three countries to more than
3500 in two countries. Overall 21.6% primary reviews were
found to be positive for one or more criteria. Three countries
had positive primary review rates of about 15%, four with rates
of about 20-25%, and one with a rate of 39%.
Perceived adequacy of medical records
Of the selected medical records, 86%were available for review.
Table 2⇓ shows the completeness of the medical records. The
lack of availability of nursing notes, pathology reports, and
procedure notes in some countries must have an effect on both
stages of review. In addition, the low rate of positive results to
the primary review criteria on readmission (average 7.5%, range
1.3-19.9%) reflects that many hospitals started a new record
each time a patient presented and hence earlier clinical
informationwas unavailable to reviewers and possibly to treating
clinicians. This low rate compares with published rates up to
23.5% for this criterion.3 4 Given that the readmission questions
were the most common trigger for second stage review in all of
the published studies that used these methods, this failure to
identify readmissions led to an important reduction in the
number of records being considered for determination of adverse
events.
Patients’ demographics and length of stay
The mean age of patients ranged from 26 to 44 across all
countries. The percentage of patients aged under 1 ranged from
2% to 13%, and the percentage of females varied from 47% to
66%, reflecting that some countries selected hospitals with a
preponderance of obstetric and paediatric patients. Figure 1⇓
shows that the adverse event rate increased with patients’ age.
The median length of stay ranged from 2 to 7 days, and the
mean varied from 3.3 to 13.4, reflecting variation in local
practice and case mix. The adverse event rate increased with
length of hospital stay, starting at 4% increasing to 25% for
stays of 30 days (fig 2⇓). Contrary to the study protocol, 2215
cases in which the patients stayed for one day were inadvertently
included in the study population and are included in the length
of stay figures above. If the adverse event rate is recalculated
with these cases excluded it increases to 8.8%.
Reliability
The reliability at screening level compared well with that
reported for previous studies, which have reported κ of
0.67-0.70. Data on reliability of the primary review were
available from six of the eight countries. In four of these the κ
score was very good (0.85-0.88), in one good (0.77), and in one
poor (0.33). Reliability testing at the secondary review level for
determination of adverse events was not completed.
Frequency and preventability of adverse
events
Table 3⇓ shows the adverse event rate by country, which varied
from 2.5% to 18.4%, the percentage of adverse events that were
judged as preventable, and the percentage of hospital admissions
that were associated with an adverse event that resulted in the
death of the patient. These adverse events could have occurred
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Box 1 Scales for physicians to judge causation and preventability of adverse events
Causation
After due consideration of the clinical details of the patient’s management, irrespective of preventability, what level of confidence do you
have that the healthcare management caused the injury?
Virtually no evidence of management causation
Slight to modest evidence of management causation
Management causation not likely (less than 50/50, but “close call”)
Management causation more likely (more than 50/50, but “close call”)
Moderate to strong evidence of management causation
Virtually certain evidence of management causation
Preventability
Rate, on a 6 point scale, your confidence in the evidence for preventability of the adverse event:
Virtually no evidence of preventability
Slight to modest evidence of preventability
Preventability not quite likely (less than 50/50, but “close call”)
Preventability more than likely (more than 50/50, but “close call”)
Strong evidence of preventability
Virtually certain evidence of preventability
before and caused the admission to hospital or occurred during
the admission.
There were 17 general public hospitals with fewer than 20% of
admissions being for obstetrics. These hospitals had a higher
adverse event rate of 11.6%, rather than 8.2%. This shows the
impact of case mix on adverse event rates. Detailed data (such
as international classification of diseases (ICD) codes or
diagnosis related group (DRG)) were not available from the
study hospitals, so more detailed adjustment for case mix was
not possible.
When we increased the adverse event causation threshold from
at least 2 to at least 4, the number of adverse events fell from
1277 to 949 and the overall adverse event rate from 8.2% to
6.1%.
Up to 83% (range 55-93%) of adverse events were judged to
be highly preventable, with the remainder considered
non-preventable or as having insufficient data to make a
determination. About 30% of adverse events were associated
with the death of the patient, which equates to nearly 2% of
patients in hospital across the eight countries sustaining an
adverse event that was associated with their death.
Disability resulting from adverse events
Table 4 shows the outcomes attributed to the 958 adverse events
coded for disability⇓. Of these, 305 (32%) patients recovered
fully within 30 days, 154 (16%) recovered fully in six to 12
months, 111 (14%) sustained permanent disability, and 288
(30%) died from causes associated with the adverse event. Each
adverse event caused an average of 9.1 additional days in
hospital for the records reviewed in this study.
Types of error causing adverse events
Figure 3⇓ shows that the most common type of adverse event
was caused by therapeutic error (34.2%, range 4-49%), followed
by diagnostic error (19.1%, 12-41%) and operative (18.4%,
7-47%). Therapeutic error indicates that a diagnosis has been
made but an appropriate therapeutic response was either not
ordered or not delivered. Diagnostic error indicates either failure
to make a diagnosis or to do so in a timely manner or the failure
to make a correct diagnosis from provided information.
Operative adverse events occurred more in the peri-operative
period but this also includes those occurring during the actual
procedure.
Impact of comorbidity on rate of adverse
events
Table 5⇓ shows that patients with chronic illnesses were at a
higher risk of adverse events when in hospital. Among patients
taking any regular drugs, the adverse event rate goes up to 11.9%
compared with 12.4% for patients with diabetes mellitus and
15.3% for those with malaria.
Clinical context for the adverse event
As part of the secondary review, the complexity and urgency
of cases with adverse events and also the degree of deviation
from the accepted norm for care were assessed in a structured
fashion. Adverse events predominantly occurred when there
was general consensus on diagnosis and treatment and in
relatively non-complex settings. Figure 4⇓ shows that deviation
from the accepted clinical norms of management was judged
as inappropriate in many cases.
Contributory factors to adverse events
Reviewers were asked to code contributory factors to the adverse
event (fig 5⇓). Inadequate training or supervision of clinical
staff was the single largest category, followed by absence of or
the failure to implement a relevant protocol or policy. Hence
failures in clinical process rather than the absence of essential
resources accounted for most contributory factors to the adverse
events in this study. This table might provide a skewed picture
because the nature of review of medical records means it is more
likely to provide a focus on individual performance and not
easily identify the system based failures that often lie behind
the mistakes of individuals.
Discussion
This large scale review of records of patient safety in developing
and transitional countries indicates that the scale of preventable
disability and death from healthcare in the Middle East and
Africa is a serious public health problemwithmajor implications
for health policy, planning, and resource allocation. Though we
were able to review medical records and detect adverse events,
the reported rate of just over 8% probably represents an
underestimate of the true rate. This underestimate might be quite
large but is more likely to affect less serious events.
Retrospective review of medical records was selected as an
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already established method and was shown to have limitations,
which contribute to this underestimation, but none the less was
able to generate the information in this report.
Potential underestimate of adverse event rate
The average adverse event rate of 8.2% across the eight
countries, ranging from 2.5% to 18.4%, is similar to that reported
in other studies using these methods, in which the rate is about
10%.4 10 The proportion of preventable adverse events, however,
is significantly higher at 83% compared with about 50% found
in previous studies. The high preventability rate could imply
that some reviewers might have confused causation and
preventability and hence excluded less preventable adverse
events from being considered in the overall pool. This would
lead to an erroneous lowering of adverse event rate. It is
important to note that the physician reviewers were from the
participating countries and used a definition of preventability
based on the standard practice in the country. The high rate of
preventability can therefore not be explained by the reviewers
expecting local care to meet international standards, if they
differ. In addition the percentage of adverse events associated
with deaths is also much higher at 30% than the 4-15% reported
previously.3-5 This could be because of under-reporting of
adverse events resulting in minimal disability compared with
published studies from more developed economies or could
reflect that patients in hospital are sicker in these countries. This
again might suggest a further underestimate of the adverse event
rate compared with published literature.
Contributors to variation in adverse event
rates between hospitals
There are several possible reasons for the variability between
adverse event rates in the participating countries. In addition to
possible variation in the quality of healthcare actually provided
to patients, there are also methodological reasons that might
account for some of the reported variation. The variable
completeness of the medical record, and hence the ability of
reviewers to detect clinical events, must have an effect that
would lead to under-reporting in less adequate records.
Particularly noteworthy is the low rate of positive screening at
the primary review, which would preclude the record from
further review. The rate in this study of nearly 22% is lower
than in the studies from the United States (26%),2 Australia
(44%),3 Canada (41%),4 and England (40%).11 The criteria
indicating readmission were the most frequent triggers for
further review in these four published studies but were not found
in most of the records in this report. This could mean that
readmissions had not occurred and might not be as useful a
trigger in developing countries or that readmissions did occur
but were not detectable from the medical record for reasons
mentioned earlier. Given that the reliability scores for the first
screen were good, it is unlikely that this difference is totally
accounted for by reviewer performance. The limitations inherent
to the methods of retrospective record review are well
understood and reported elsewhere.12 13 Additionally in this
study, the language in the medical record varied and within
some countries a single medical record could have
documentation in three different languages, not all readily
understood by some reviewers or all care givers.
The performance of the reviewers can also lead to variation in
reported adverse event rates. Selection and training of reviewers
was standardised within budget and logistic constraints. The
country leaders were trained by the international faculty who
also oversaw some of the data collection in most countries. The
country leaders would then train reviewers in the individual
countries with standardised manuals and data collection tools.
The time for training was about four days for the country leaders
and in most countries at least two days for the reviewers, who
then had further supervision from the country leaders during
the record review period.
Data entry was standardised for local data entry teams in their
countries, uploading data with a specifically designed web based
program. This resulted in unification of the presentation and
analysis of data, but there were problems with the interface.
Failure of internet connections led to problems with missing
data and duplication of records. Although this had a major
impact on data entry and cleaning, it affected a maximum of
3% of the selected records and hence could contribute only a
small amount to the adverse event variation or under-reporting.
The case mix and age differences could account for some of the
variation seen in the adverse event rates. This study bears out
previous reports that the rate of adverse events increases with
age and also that it is relatively lower in obstetric and paediatric
populations than in other diagnostic categories. Hence, with 11
of the 26 hospitals having 20-90% of their admissions being for
obstetric care, the adverse event rate would be expected to be
lower for this population and contribute to variation between
hospitals and countries. Many of the previously published
studies on adverse events excluded obstetric and psychiatry
patients.
The potential difficulty of engaging a larger number of hospitals
in each country, both politically and logistically, and also the
considerable cost increase that would be required to study a
representative sample from each country, precluded systematic
selection of hospitals that would have provided a nationally
representative sample for each country. The country research
teams have informally commented that the hospitals chosen in
each of their countries included hospitals that would be
considered anecdotally as providing some of the best care in
that country. Hence this report provides data on the hospitals
studied but does not give an adverse event rate for each country
because of the method of hospital sampling. Nevertheless, our
objective was not to produce nationally representative figures
but to produce valid data from a selection of hospitals that would
be indicative of the extent of the problem in these hospitals as
well as being useful for raising awareness at the national and
international level. The fact that many of the selected hospitals
were considered as among the best providers in their respective
countries would give a powerful message regarding the
importance of patient safety.
In summary, the data obtained in this study from 26 hospitals
admitting more than 500 000 patients a year across eight
developing and transitional countries give the best view to date
of adverse events by using previously tested methods. It does
not allow the comparison of adverse event rates between the
countries in the study.
Limitations on generalising the results
Despite these limitations, these data raise several important
points. Firstly, the problem of patient safety is not confined to
the developed economies of the world. These data, although
almost certainly an underestimate, show that patient safety is a
much bigger problem in these developing and transitional
countries, when judged by the number of preventable deaths
from adverse events, compared with reports from developed
economies. Extrapolating these figures to the activity of the
study hospitals yields a calculation that suggests that nearly 2%
of their annual about 550 000 admissions, or more than 10 000
patients, would die from adverse events in those 26 hospitals
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each year. This amounts to more than one death a day in each
of these hospitals, with most of these deaths being potentially
preventable. When compared with the cause of death data for
Egypt, these data would rank “unsafe healthcare” as the fifth
most common cause of death after cardiovascular disease,
digestive disease, infectious and parasitic disease, and cancer.
Understanding the nature and causes of harm to patients is vital
to developing strategies for improvement. The classification of
adverse events in the review form is similar to that of previous
studies. Interestingly the proportion of “therapeutic errors,”
where a diagnosis has beenmade but an appropriate therapeutic
response is not ordered or delivered, is much higher, at 34%
compared with around 7% in western studies.3Conversely drug
errors usually account for 15% of adverse events but in this
study account for only 4%. In addition to the likelihood that
fewer drugs were being routinely used, attention to basic clinical
processes is needed to ensure that fundamental diagnostic and
therapeutic steps are taken in the care of patients. Further useful
information might be contained in the narrative section of the
reviews and is the subject of further study. Box 2 provides a
series of vignettes to assist understanding of the cases coded as
adverse events.
In addition to the coding of contributory factors to the adverse
events, reviewers were asked to make comments on strategies
for prevention of the adverse event occurring again (fig 6⇓).
For some it was not possible to identify contributory factors or
methods of prevention from the medical record, but important
observations were made. Clear priority is given to improving
the training and supervision of clinicians, improving the
availability and implementation of standardised best practice
protocols, and improving record keeping. The reviewers gave
a relatively low priority to lack of clinical staffing or the
availability of necessary equipment or supplies. This is not to
contradict the healthcare workforce studies14 but to underscore
that we need improved clinical processes and supervision for
them to be effective in efforts at patient safety. Given that the
medical record is the source, it is not surprising that factors
focused on individual rather than system failures predominate
in this analysis. This does not take away fromwhat is presented
but should drive the need for further study of the context and
systems in which the care is being provided.
Conclusions
This study provides evidence on the extent and nature of patient
harm in 26 hospitals in eight developing or transitional
economies in the Middle East and Africa. Our results, despite
the study’s necessary limitations, place patient safety as one of
the major concerns for the health policy agenda in these
countries. The rates of preventable harm and death are higher
than previously reported in other studies, raising important
concerns for policy makers and practitioners. Further
confirmatory studies are required, as well as renewed efforts to
identify the underlying causes and to find solutions to patient
harm that could be feasible and able to be implemented in highly
resource constrained health systems. Importantly, this will not
be solved only by providing more staff and equipment, even if
that were immediately possible. Basic clinical processes of
diagnosis and treatment need broad attention, aided by the
provision of clinical policies and protocols standardised on best
practice and supervised in their implementation
Our study also shows that retrospective review of records can
be used in transitional and developing countries to gain
important information on occurrence of adverse events and that
the extent of preventable mortality from healthcare in patients
in these countries is higher than any published reports from
developed countries.
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Box 2 Anonymised vignettes of adverse events
• A 20 year old woman who was four months pregnant and had had recent outpatient treatment for malaria was admitted to hospital
with symptomatic anaemia and palpable splenomegaly. There was a delay in reporting of her low haemoglobin concentration and her
condition deteriorated, requiring urgent transfusion. This was performed without blood grouping or cross matching. The patient died
soon after from transfusion reaction
• A 2 year old was seen in the emergency department for fever associated with convulsion. Child was sent home without specific
diagnosis or treatment and died at home from further convulsions with progressive fever
• A 34 year old patient developed tetanus after a previous admission to a local hospital with traumatic frontal head injury, without
assessment of tetanus status or immunisation. The patient died from tetanus and its complications
• One day after a normal vaginal delivery the baby was noted to have head swelling and oozing. Computed tomography showed a skull
fracture with haematoma. After clinical deterioration and transfer to intensive care unit, the baby died from the head injury
• A 50 year old woman with diabetes was readmitted two days after discharge after laparoscopic cholecystectomy. Biliary peritonitis
was diagnosed and she was transferred to intensive care. She died some days later
• An 18 year old man was admitted with fever and irritability; malaria and typhoid fever were diagnosed. He became more sleepy and
irritable, leading to transfer to psychiatric hospital, where he subsequently died without adequate treatment for malaria and typhoid
• A 15 year old girl was discharged from emergency department after presenting after a fall from second floor of a building, complaining
of back pain and absent lower limb movement. Paraplegia was subsequently diagnosed
• A 30 year old woman was admitted twice for drainage of liquor during pregnancy. On previous admission, she complained of labour-like
pain. On the index admission, a breech presentation noted and caesarean section was performed. At surgery the uterus was noted
to be ruptured, presumably from liquor drainage, and subsequently repaired
• A 35 year old woman complained of amenorrhea for seven months. Diabetes with pregnancy was diagnosed. She was given insulin
to control her blood glucose concentration. She refused to stay in hospital and discharged herself
• An 85 year old man was admitted through the emergency department with difficulty with micturition. The diagnosis was benign prostatic
hypertrophy. He underwent surgery, from which he died 24 hours later
• An 18 year old girl was admitted through the emergency department with complaint of headache, fever, and convulsion. She received
drug treatment and was referred to the psychiatric department
• A patient was readmitted a week after laparotomy for intussusception and bowel obstruction. On representation the wound had broken
down and stool was discharging from it. At a second laparotomy, three perforations of the ileum with resulting fistulas were found.
Ileal resection and re-anastomosis was done. After few days patient was discharged without any documentation
• An obese 30 year old women (gravida 7, para 3) with uncertain dates was delivered by emergency caesarean section under general
anaesthesia because of large baby, a girl who weighed 4400 g. The woman arrested and died in the operating theatre
• A 23 year old pregnant woman, uncertain about dates, delivered vaginally. She developed postpartum haemorrhage but without close
observation or treatment. Later laparotomy and hysterectomy were performed but she died during surgery
• A 23 year old woman presented to the emergency room with severe headache and vomiting and was treated and discharged. She
returned a few hours later with deterioration of level of consciousness and was found to have a brain haemorrhage. Deterioration
continued and she died a few days later
• A 60 year old man with history of ischaemic heart disease with atrial fibrillation was admitted with acute pulmonary oedema. He
arrested after bolus intravenous injection of morphine 10 mg and hydrocortisone 200 mg, and died the same day
What is already known on this topic
With regard to healthcare of patients in hospital, several studies from developed economies show that about 10% of patients experience
harm (an adverse event) and at least half of these are preventable
While most patients recover from these events, a small percentage experience permanent disability or die; the older the patient and the
longer the stay in hospital, the higher the rate of adverse events
What this study adds
Patients admitted to hospital in developing or transitional economies experience important harms associated with healthcare
Despite methodological limitations of this study, the risk of mortality from adverse events in these patients is even higher than previously
reported
Prevention strategies must go further than the provision of more resources if they are to succeed
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Tables
Table 1| Number of records that underwent primary (RF1) and secondary (RF2) review, number positive for potential adverse event, and
number of adverse events in eight developing countries
Adverse event rate/admission
Secondary screen (RF2)†Primary screen (RF1)*
Country No (%) of adverse eventsNo in sampleNo (%) positiveNo in sample
6.081 (24)342342 (25)1358A
2.593 (17)546550 (15)3769B
14.5281 (67)422422 (22)1938C
14.8146 (38)383383 (39)984D
8.276 (51)149149 (16)931E
5.5218 (23)946946 (24)3977F
8.377 (57)136136 (15)930G
18.4305 (73)418423 (26)1661H
8.21277 (38)33453351 (22)15 548Total
*Initial screening stage by nurse or junior doctor for presence of one or more of 18 specific criteria indicating potential adverse event.
†Review by senior physician of positive records from primary review to determine presence of adverse event and preventability.
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Table 2| Proportion of records that had evidence for variables shown from total number assessed for quality of medical record in eight
developing countries
Proportion (%) with evidence for elements shown†
No of records
available*Country
Discharge
summaryPathology reports
Procedure
documentation
Nursing progress
notes
Medical progress
notes
Initial medical
assessment
6624906689961358A
9745909890963769B
865299471001001938C
375292829091984D
647593959798931E
2086694695993977F
86529947100100930G
8522804380931661H
67688572929715 548Total
*Indicates number of completed first review forms (RF1).
†Does not indicate completeness or accuracy of those elements.
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Table 3| Frequency of adverse events, percentage of preventable adverse events, and percentage of admissions associated with adverse
events that resulted in death* in eight developing countries
% admissions resulting in death% preventability†Adverse event rate/100 admissions*No of records reviewedNo of hospitalsCountry
1.2572.5 (62.8 to 82.2)6.0 (4.7 to 7.3)13583A
0.6183.3 (75.7 to 90.9)2.5 (2.0 to 2.9)37695B
3.276.6 (71.6 to 81.6)14.5 (12.9 to 16.1)19382C
3.5885.6 (79.9 to 91.3)14.8 (12.6 to 17.0)9842D
0.7555.1 (43.9 to 66.3)8.2 (6.4 to 10.0)9312E
1.6284.0 (79.1 to 88.9)5.5 (4.8 to 6.2)39776F
1.2985.7 (77.9 to 93.5)8.3 (6.5 to 10.1)9302G
4.2892.8 (89.9 to 95.7)18.4 (16.5 to 20.3)16614H
1.8583.08.215 54826Total
*Score ≥2 on 6 point scale (see text), as well as injury and disability, required for determination of adverse event.
†Score ≥4 on 6 point scale (see text) required for adverse event to be considered as preventable.
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Table 4| Frequencies (percentage) for disability from adverse events associated with healthcare in eight developing countries
TotalHGFEDCBADisability/outcome
305 (32)65 (25)39 (53)57 (32)27 (41)43 (301)34 (32)35 (41)5 (10)Minimal impairment
Moderate impairment:
119 (12)24 (9)14 (19)28 (16)13 (20)14 (10)6 (6)12 (14)8 (16)1-6 months
35 (4)9 (4)1 (1)3 (2)3 (5)13 (9)05 (6)1 (2)6-12 months
Permanent disability:
54 (6)12 (5)6 (8)3 (2)8 (12)18 (13)1 (1)2 (2)4 (8)<50%*
57 (6)30 (12)06 (3)1 (2)14 (10)1 (1)1 (1)4 (8)>50%*
19 (2)5 (2)012 (7)01 (1)001 (2)Permanent nursing
5 (1)4 (2)01 (1)00000Institutional care
288 (30)71 (28)12 (16)62 (35)7 (11)35 (25)61 (58)23 (27)17 (34)Death
76 (8)38 (15)2 (2)7 (4)7 (11)3 (2)2 (2)7 (8)10 (20)Unknown
95825874179661411058550Total
*=50% was not an option for reviewer.
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Table 5| Comorbidity and rate of adverse events in review of medical records in eight developing countries
Adverse event %% of study populationComorbidity
11.914.8Receiving regular drug treatment
11.87.2Hypertension
12.45.6Diabetes mellitus
15.32.3Malaria
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Figures
Fig 1 Rates of adverse events with age in patients in hospital in developing countries
Fig 2 Rate of adverse events by length of stay, indicated as average for index admission in sampled records, per hospital.
Rates increases with length of stay, starting at 4% and increasing to 25% for stays of 30 days. Length of stay is shown as
average for index admission in sample record per hospital
Fig 3 Type of error related to occurrence of adverse event shown as percentage of 890 adverse events with codes for this
classification (multiple coding possible)
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Fig 4 Degree of deviation of management from accepted norm in patients who experienced adverse event in hospital
Fig 5 Factors contributing to the adverse events. Coding was not possible for all adverse events and multiple codes could
be used for same event
Fig 6 Strategies for preventing recurrence of 1277 adverse events from eight countries in adverse event study. Coding was
not possible for all adverse events and multiple codes could be used for same event
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